Melanotan II
- Category
- Skin & Cosmetic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A cyclic analog of alpha-MSH that activates the melanocortin receptors, sold for tanning, erectile function, and appetite suppression. Human evidence is good for erections and tanning but weak for appetite and sun protection. Most users get nausea and flushing, and the real concern is that it stimulates melanocytes with a possible melanoma link, plus case reports of rhabdomyolysis and priapism. It is not an approved US drug, and the FDA warns against it.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Melanotan II is a synthetic seven-amino-acid peptide developed at the University of Arizona that activates multiple melanocortin receptors, triggering tanning, appetite suppression, and sexual arousal simultaneously. Unlike Melanotan I (Scenesse), which selectively targets the tanning receptor MC1R, Melanotan II is non-selective and has never received FDA approval due to its wide range of side effects. A derivative called bremelanotide (PT-141 / Vyleesi) was later developed from it as a targeted sexual health treatment.
How it works in the body
A cyclic analog of alpha-MSH that activates multiple melanocortin receptors (MC1R through MC5R). MC1R activation darkens skin. MC3R/MC4R activation in the brain suppresses appetite and triggers sexual arousal. Its broad receptor activity produces tanning, appetite suppression, and erectile effects simultaneously.
Research overview
Melanotan II stimulates eumelanin (dark pigment) production through MC1R for tanning, while its MC4R activity produces erectile function, sexual arousal, and appetite suppression. It never advanced past Phase I/II clinical trials because its non-selective receptor activation made side effects too broad and unpredictable. The research ultimately led to bremelanotide (PT-141), a nonselective melanocortin receptor agonist that received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD). Melanotan II remains unapproved and is widely sold through unregulated online sources, raising significant quality and safety concerns.
Who researches Melanotan II?
Commonly researched by
People researching weight management options
Studied for effects on body composition, appetite regulation, or metabolic rate.
People exploring hormone and sexual health
Researched for effects on hormone levels, sexual function, or fertility.
Important considerations for
Those with History of melanoma or dysplastic nevi
AbsoluteStimulates melanocyte activity. Can darken existing moles and may promote melanoma in predisposed individuals.
Those with Autoimmune skin conditions
ModerateMelanocyte stimulation may worsen autoimmune skin conditions like vitiligo.
Those with Cardiovascular disease
ModerateCan increase blood pressure and heart rate through melanocortin receptor activation.
Those who are pregnant or breastfeeding
AbsoluteNo safety data. Affects multiple hormone systems.
Safety & interactions
Do not use if
History of melanoma or dysplastic nevi
AbsoluteStimulates melanocyte activity. Can darken existing moles and may promote melanoma in predisposed individuals.
Autoimmune skin conditions
ModerateMelanocyte stimulation may worsen autoimmune skin conditions like vitiligo.
Cardiovascular disease
ModerateCan increase blood pressure and heart rate through melanocortin receptor activation.
General cautions
Pregnancy
AbsoluteNo safety data. Affects multiple hormone systems.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
NOT FDA-approved; FDA explicitly warns against use
HighTGA public warning (tga.gov.au); FDA import/enforcement actions; MHRA warning (2009)
Rhabdomyolysis (case reports)
ModerateNelson, Bryant & Aks, Clin Toxicol (Phila) 2012;50(10):1169-73
Renal infarction (case report)
LowPeters et al., CEN Case Rep 2020, DOI 10.1007/s13730-020-00447-z
Possible melanoma association; stimulates melanocyte proliferation
ModeratePMC3663356 (FAMMM teenager mole changes); eruptive dysplastic nevi case series (Actas Dermosifiliogr)
Nausea, facial flushing in most users
HighPMID 8637402 (Dorr et al. 1996); PMID 9679884 (Wessells et al. 1998)
Priapism (prolonged painful erection)
ModerateDreyer et al., Sex Med / Urol Case Rep 2021 (S2050116120301859); Nelson 2012 (priapism companion report)
Interaction summary(5)
Rated by direction with this peptide
PDE5 inhibitors (sildenafil, tadalafil)
SynergisticModerateAdds a distinct central erectogenic mechanism on top of PDE5 inhibition, potentially enhancing erections but raising the risk of prolonged/priapic response and additive blood-pressure effects.
Mechanism + Wessells erectile trials (PMID 9679884); melanocortin class caution
Antihypertensive medications / drugs affecting blood pressure
CautionModerateMelanocortin agonists transiently raise blood pressure and lower heart rate (documented for the MT-II derivative bremelanotide/Vyleesi; new-onset hypertension reported in an MT-II renal-infarction case), which can blunt antihypertensive control.
Vyleesi (bremelanotide) FDA label; Peters et al., CEN Case Rep 2020
Concurrent UV exposure / tanning beds
CautionModerateCombining MT-II with UV/sunbed exposure is repeatedly linked in case reports to rapid nevus changes and melanoma, especially in genetically susceptible (FAMMM) users; the two melanocyte-stimulating exposures compound risk.
PMC3663356 (FAMMM teenager, Melanotan + sunbed)
Sympathomimetic stimulants (amphetamines, cocaine)
CautionTheoreticalThis is purely mechanistic/theoretical. Plausible additive vasoconstriction, hypertension and cardiovascular/renal toxicity, since MT-II itself can produce a sympathomimetic toxidrome at supratherapeutic dose. Note the index MT-II rhabdomyolysis case actually screened NEGATIVE for cocaine/amphetamines, so it does not evidence a stimulant co-exposure; no specific interaction is formally characterized.
Mechanistic; Nelson et al., Clin Toxicol 2012 (MT-II sympathomimetic toxidrome; stimulant screen negative)
Oral naltrexone
CautionTheoreticalThe related melanocortin agonist bremelanotide reduces oral naltrexone exposure (~60% lower Cmax, ~40% lower AUC via slowed gastric motility); the Vyleesi label recommends avoiding co-use with oral naltrexone for alcohol/opioid dependence. Extrapolation to MT-II is mechanistically plausible but unproven, hence Theoretical.
Vyleesi (bremelanotide) FDA label
Known risks(8)
NOT FDA-approved — FDA explicitly warns against use
Rhabdomyolysis (dangerous muscle breakdown) — case reports
Renal infarction — case report (50% kidney affected)
Possible melanoma association — stimulates melanocyte proliferation
Nausea, facial flushing in most users
Priapism (painful prolonged erection requiring emergency treatment)
Changes to moles/freckles making melanoma detection harder
Unregulated products: unknown purity, contamination risk, inconsistent dosing
Drug interactions(2)
PT-141 (Bremelanotide)
Both are melanocortin agonists. PT-141 is a derivative of MT-II. Combining would amplify side effects.
Blood pressure medications
MT-II can affect blood pressure. Monitor when combined with antihypertensives.
Research & benefits
Evidence base
- Evidence Level
- Early Clinical (Phase I/II)
- Total Studies
- 15
- Human Studies
- 6
Phase I (Dorr 1996, n=3): tanning confirmed. Double-blind RCT (Wessells 2000, n=20): potent erectile effects. Never advanced to Phase III. Derivative PT-141 completed full development. Case reports of serious AEs (rhabdomyolysis, renal infarction, melanoma association).
Researched for(5)
Rated by confidence in the evidence
Skin tanning
MediumMC1R activation drives eumelanin; visible darkening after 5 injected doses, strongest in fair skin.
PMID 8637402 (Dorr et al., Life Sci 1996)
Erectile function
HighIn a small human trial, 17 of 20 men with erectile dysfunction achieved erection without stimulation.
PMID 9679884 (Wessells et al., J Urol 1998); PMID 11035391 (Wessells et al., 2000)
Sexual desire/arousal
MediumSmall controlled studies found increased desire in men; MT-II research later led to PT-141.
PMID 11035391 (Wessells et al., 2000)
Appetite suppression
LowMC4R-linked, dose-dependent eating reductions in animals; only incidental human reports so far.
PMC10152796 (nucleus accumbens MT-II feeding study); decreased appetite reported incidentally in PMID 9679884
UV photoprotection
SpeculativePreliminary; a related analog suggests possible sunburn protection, but not shown for this peptide.
Afamelanotide/Scenesse EPP data (analog, not MT-II)
Benefits(5)
Skin tanning
Erectile function
Sexual desire/arousal
Appetite suppression
UV photoprotection
Key studies(4)
Dorr RT et al.
Life Sciences
1996
First human trial. Increased pigmentation in 2/3 subjects. Established 0.025mg/kg dose.
Wessells H et al.
Int J Impot Res
2000
DB-RCT: 17/20 ED men achieved erection. 41 min rigidity. Desire increased 68% vs 19%.
Hadley ME
Peptides
2005
Documented accidental discovery of sexual effects. Led to bremelanotide development.
Peters B et al.
CEN Case Reports
2020
First renal infarction case. 50% kidney affected after 27mg over 6 months.
What research suggests over time
Hours-Days
Phase II (sexual)Acute erectile effect within ~40 minutes on SC dosing (Wessells 2000: 17/20 ED men responded; 41-min rigidity duration).
Weeks 2-4
Phase I/II (tanning)The three-person MT-II pilot detected increased pigmentation in two participants one week after treatment ended.
Long-term
Phase I/II (discontinued)Never advanced past Phase II; FDA warning letters issued. The PT-141/bremelanotide derivative was the version that earned FDA approval (Vyleesi 2019).
Regulation & availability
Why researchers look at it
Early studies confirmed potent tanning and erectile effects (double-blind RCT, n=20), but non-selective melanocortin activation produced side effects too broad for pharma development — its greatest legacy is spawning the FDA-approved drug PT-141 (Vyleesi). Case reports of rhabdomyolysis, renal infarction, and melanoma associations have led regulatory agencies worldwide to warn against unregulated use.
- FDA status
- Unapproved drug. FDA warning letters issued (e.g., Melanocorp Inc.). Never completed approval process. Derivative PT-141 (Vyleesi) FDA-approved 2019 for HSDD. Melanotan I (afamelanotide/Scenesse) approved 2019 for EPP — distinct peptide.
- WADA status
- Not explicitly listed but falls under S0 (non-approved substances)
- Prescribability
- NOT FDA-approved. Unapproved drug per FDA. Warning letters issued. Derivative PT-141 (bremelanotide/Vyleesi) is FDA-approved.
- Availability
- NOT FDA-approved. FDA considers it unapproved drug with active enforcement. FDA, TGA (Australia), HPRA (Ireland) all warn against use.
International status
EU
Not approved; banned in some countries
UK
MHRA warns against use
US
Not approved; FDA warning letters issued
Australia
Not approved; TGA warnings issued
Regulatory timeline(4)
- 1996Phase I trialDorr et al. first human study (n=3)
- 2000ED RCT publishedWessells et al. (n=20) — potent erectile effects
- OngoingFDA enforcementFDA considers MT-II an unapproved drug. Warning letters to sellers.
- 2019PT-141 approved insteadDerivative bremelanotide (Vyleesi) received FDA approval for HSDD
Sources & FAQs
Research sources(4)
Frequently asked questions(5)
MT-I vs MT-II?
MT-I (afamelanotide) is linear, selective MC1R, FDA-approved for EPP. MT-II is cyclic, non-selective MC1R/MC3R/MC4R/MC5R, unapproved.
MT-II vs PT-141?
PT-141 (bremelanotide) is derived from MT-II and nonselectively activates several melanocortin receptors; MC1R and MC4R binding are most relevant at therapeutic doses. FDA-approved 2019 for HSDD (Vyleesi). MT-II remains unapproved.
Is it safe?
Not rigorously tested. AEs: nausea, flushing, priapism, rhabdomyolysis, renal infarction, mole changes, possible melanoma association. Unregulated products carry contamination risk.
Does it cause cancer?
Not definitively established. Case reports of melanoma in users. Stimulates melanocyte proliferation. 2021 review: elevated risk likely explained by UV-seeking behavior.
Can a doctor prescribe it?
Melanotan II is unapproved. No qualifying 503A bulk-compounding basis was identified. Its withdrawn nomination does not provide Category 1 enforcement discretion, and FDA retains significant safety concerns.